Filing Flows › Health Care › DexCom (DXCM)
DexCom (DXCM) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · DexCom (DXCM) Q3 2026 earnings results →
Q3 2026 Revenue up 11% year over year to $1.3B · 20¢ of every $1 of revenue kept as net profit · operating margin 24.3%
DexCom made $1.3B in Q3 2026 (+11% Y/Y). Operating margin 24.3%, net earnings $275M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.3B in Q3 2026, up 11% year over year and up 3% from the previous quarter.
Gross margin was 64.3%, up 3.8 points from Q3 2025. Operating profit was $0.33B, a 24.3% margin (up 4.3 points year over year). Of the extra revenue versus Q3 2025, 63% reached operating profit, above the 20% margin then. Operating expenses grew 10% against revenue growth of 11%. The fastest-growing cost line was SG&A (+13%). Net earnings were $0.28B, down 3% year over year. The effective tax rate was 17.8%.
Operating cash flow was $0.33B (down 51% year over year), 118% of net earnings. Non-cash charges added back $0.07B of depreciation and amortization and $0.04B of share-based compensation. Working capital and other items used $0.06B. Capital expenditures of $0.05B left free cash flow of $0.27B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $1.3B | +11% | 24.3% | $275M | $326M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $1.3B | +13% | 24.3% | $249M | $269M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $1.2B | +15% | 21.4% | $200M | $526M |
| Q4 2025 | 10-K | Feb 12, 2026 | $1.3B | +13% | 25.6% | $267M | $294M |
| Q3 2025 | 10-Q | Oct 30, 2025 | $1.2B | +22% | 20.1% | $284M | $660M |
| Q2 2025 | 10-Q | Jul 30, 2025 | $1.2B | +15% | 18.4% | $180M | $303M |
| Q1 2025 | 10-Q | May 1, 2025 | $1.0B | +12% | 12.9% | $105M | $184M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About DexCom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
In its own words, from its 8-K, filed Jul 30, 2026.
DexCom against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +5%. Operating margin: 24.3% against the peers' median 15.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DXCM DexCom | Q3 2026 | $1.3B | +11% | 24.3% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: DexCom 10-Q on SEC EDGAR · CIK 1093557 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns DXCM and who is buying
More on DXCM
- How DexCom makes money: revenue by segment
- DexCom next earnings date and what analysts expect
- DexCom stock forecast, price target and fair value
- Who owns DexCom stock: holders, funds and Congress trades
- DexCom guidance and outlook
- Is DexCom a takeover target? LBO and rumors
- DexCom recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results